See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12th Annual Product Reference Guide
  • Insulin Syringe Chart
  • Insulin Pen Needles Chart
  • Fast-Acting Glucose
  • Sharps Disposal
  • Blood Glucose Meters Chart
  • Insulin Pumps Chart
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Top Rated

Diabetes Medications Research Article Archives

May 2011

Maple Syrup-A Sweet Surprise

Meet the latest superfood: maple syrup.  Wait a minute...maple syrup? The super-sugary stuff poured on pancakes and waffles and used to glaze hams? That maple syrup?

comments 9 comments - Posted May 24, 2011

Danish Study Reports Three Diabetes Drugs Best for Lowering Cardiovascular Risk

A Danish study of 107,806 adults taking various diabetes medications has found that three drugs are the most effective at lowering the risk of cardiovascular disease and death: metformin, gliclazide (not marketed in the US), and repaglinide (Prandin). Other common diabetes medications, including glimepiride, glibenclamide (glyburide), glipizide, and tolbutamide, were linked to a higher risk of death both from all causes and from heart attack and stroke.  

comments 1 comment - Posted May 13, 2011

February 2011

Statins May Prevent Diabetic-Related Blindness

New University of Georgia research has found that a statin drug that is often known by the brand-name Lipitor may help prevent blindness in people with diabetes. In a study using diabetic rats, lead author Azza El-Remessy, assistant professor in the University of Georgia College of Pharmacy, and her colleagues found that statins prevent free radicals in the retina from killing nerves important to maintaining vision. The results of the study are published in the March edition of the journal Diabetologia.

comments 0 comments - Posted Feb 23, 2011

January 2011

Kombiglyze Komes to a Pharmacy Near You

The kuriously named Kombiglyze XR, a combination of Onglyza (saxagliptin) and the old reliable metformin, has arrived at pharmacies and is available by prescription to people with type 2 diabetes. It's similar to Janumet, an older medication that's a combination of Januvia (sitagliptin) and metformin.

comments 0 comments - Posted Jan 25, 2011

Taking Your Medicine Is Healthy for the Healthcare System

Taking your medicine can lead to quite a windfall in reduced medical claims, according to a study recently published in Health Affairs. Over the course of a year, patients with diabetes who took their medications as directed saved their insurance companies a handsome $3,756 compared to people who didn't, even after claiming as much as $1000 for those very medications. The money was saved because the patients spent less time at the emergency room and in the hospital, a nice benefit in itself.

comments 1 comment - Posted Jan 11, 2011

Sitagliptin (Januvia) Lowers Blood Sugar in People With Type 1 Diabetes

Sitagliptin (Januvia) has long been used to reduce blood sugar in people with type 2 diabetes, but a new study indicates that it can do the same for those with type 1 diabetes. Sitagliptin is a DPP-4 inhibitor; that is, it inhibits, or temporarily prevents, the enzyme DPP-4 from destroying a helpful hormone called GLP-1. GLP-1, which is released by the gut when food arrives there from the stomach, lowers blood sugar by causing the release of insulin, reducing the secretion of glucagon, and slowing stomach emptying and nutrient absorption.

comments 3 comments - Posted Jan 7, 2011

A Personal Journey to the New York Historical Society's Diabetes Exhibit

My trip began as I flew from Dallas to my home town of Philadelphia and then caught an early Amtrak train to New York City.  Growing up in the Philadelphia area had given me an appreciation for U.S. history, but today I was going to learn something new: the history of diabetes.  My daughter, Sarah, was diagnosed with type 1 diabetes in 2003, yet I didn't know much about the history of the disease. Living every day with the stress and worry that many parents have, I felt I had no time to spend learning how we got to the modern treatments we have today.  I had focused only on doing my job as caregiver and supporter of my daughter.  I was looking forward to learning something new.

comments 10 comments - Posted Jan 3, 2011

December 2010

Einstein College of Medicine Receives $600,000 Grant to Study Resveratrol's Impact on Pre-Diabetes

The Albert Einstein College of Medicine at Yeshiva University in New York City has received a $600,000 grant from the American Diabetes Association to study the effects of resveratrol on lowering impaired glucose tolerance in older adults.

comments 2 comments - Posted Dec 30, 2010

Combining exenatide with insulin may be ‘best result ever' for diabetes patients

A new study finds that combining the newer diabetes drug exenatide with insulin provides better blood sugar control in patients with type 2 diabetes than insulin alone and helps promote weight loss.

comments 1 comment - Posted Dec 27, 2010

November 2010

Recession Weighs Heavily on People With Diabetes

The economic recession has hammered people with diabetes, according to a new survey. Many say that their health has been harmed by the crisis, and more expect their health to suffer in the future. What's more, most don't expect the government's health reform bill to improve their situation.

comments 1 comment - Posted Nov 28, 2010

A New Approach for Type 2 Diabetes

A new drug for type 2 diabetes started showing up in drugstores this week, according to manufacturer Santarus. The FDA-approved drug, called Cycloset, takes an distinctive -- and not well understood -- approach to reducing blood sugar levels. The pill apparently works by increasing dopamine activity in the hypothalamus, a part of the brain. Dopamine is a brain chemical that plays a big role in people's behavior, mood, and ability to sleep. Scientists theorize that glucose intolerance and insulin resistance may in part result from abnormal activity of this chemical, and that upping dopamine activity may iron out these problems.That's the theory, at least: the drug's exact workings aren't known.  But it seems to do the trick.

comments 0 comments - Posted Nov 24, 2010

October 2010

Surgeons Create Functional Artificial Pancreatic Tissue

In a proof-of-concept study presented at the 2010 Annual Clinical Congress of the American College of Surgeons, the researchers note that the matrix not only helps to understand the micro-architecture of the pancreas, but also prolongs the survival and preserves the function of the islets. Islets survived longer in the bio-artificial matrix than in conventional transplantation sites, and they produced significantly more insulin when challenged with glucose.

comments 0 comments - Posted Oct 30, 2010

August 2010

Gene testing could have saved weight-loss drug

(Reuters) - Genetic testing might have helped identify people who would become depressed or suicidal while taking Sanofi-Aventis' weight loss drug Acomplia, which might have helped keep the drug on the market, U.S. researchers said on Thursday.

comments 0 comments - Posted Aug 19, 2010

The Sanford Project Launches Research Study to Find a Cure

"The objective of this clinical trial (research study) is to determine if the medications can rescue the few beta cells that remain soon after the diagnosis of type 1 diabetes; and whether new beta cells can even be regenerated," commented Alex Rabinovitch, MD, Principal Investigator of the trial and Associate Director of The Sanford Project. "The investigational combinations of these medications could possibly allow patients to decrease or no longer need to inject insulin to keep their blood levels under proper control."

comments 0 comments - Posted Aug 12, 2010

Wouldn’t it be Great if You Could Pop a Pill and Lose Weight?

And wouldn't it be great if that pill weren't something advertised on late-night TV, but rather a legitimate treatment? A drug called rimonabant, introduced in Europe, seemed to fit the bill at first, but it was pulled from the market in late 2008 due to concerns about psychiatric side effects.

comments 0 comments - Posted Aug 10, 2010

Victoza® Achieved Improved Blood Sugar Control in African-Americans With Type 2 Diabetes

Novo Nordisk presented results demonstrating that once-daily Victoza® (liraglutide [rDNA] injection) achieved significantly greater improvements in blood sugar control compared to placebo among African-American patients with type 2 diabetes. The meta-analysis of phase 3 data from the Liraglutide Effect and Action in Diabetes (LEAD) trials were presented at the 2010 National Medical Association Annual Convention & Scientific Assembly.

comments 0 comments - Posted Aug 5, 2010

July 2010

New York Historical Society Brings to Life the Dramatic Story of the Discovery of Insulin

NEW YORK, NY, July 26, 2010 - Recalling the desperate fight for life that used to be waged by juvenile diabetes patients, and commemorating the events of 1921 that inaugurated a new era of hope for them and their families, the New York Historical Society will present the exhibition Breakthrough: The Dramatic Story of the Discovery of Insulin from October 5, 2010 through January 31, 2011. Exploring the roles of science, government, higher education and industry in developing and distributing a life-saving drug, the exhibition will bring to life the personalities who discovered insulin and raced to bring it to the world and will tell the story of one extraordinary New York girl-Elizabeth Evans Hughes, daughter of the leading statesman and jurist Charles Evans Hughes-who was among the very first patients to be saved.

comments 0 comments - Posted Jul 26, 2010

U.S. Advisers Reject Vivus' Fat Pill

(Reuters) - The first new prescription weight-loss pill in more than a decade failed to win backing from advisers, who said safety concerns about the drug outweighed its ability to help obese patients shed pounds.

comments 0 comments - Posted Jul 19, 2010

Avandia and the FDA Panel: Scientific Leaders Urge Diabetes Patients to Talk with their Doctor before Making Changes to their Medication Use

The U.S. Food and Drug Administration's (FDA) Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee has completed their evaluation of the scientific research available on the safety of rosiglitazone. The deliberations of the panel reflected the complexity of the issues, with several members voting to add additional warnings or to withdraw the drug from the U.S. market. Ultimately, the final recommendation was to allow Avandia to remain on the market. Now that the expert panel has concluded its meeting, the FDA will review their recommendations and make the final decision on whether the drug remains available to patients.

comments 0 comments - Posted Jul 15, 2010

Johns Hopkins Team Discovers Sweet Way to Detect Pre-Diabetes

Having discovered a dramatic increase of an easy-to-detect enzyme in the red blood cells of people with diabetes and pre-diabetes, Johns Hopkins scientists say the discovery could lead to a simple, routine test for detecting the subtle onset of the disease, before symptoms or complications occur and in time to reverse its course.

comments 0 comments - Posted Jul 15, 2010

Intensive BG Control and the Onset of Organ Damage in Type 2s

Data from the massive ACCORD study on intensive blood sugar control shows that lowering blood sugar levels in people with longstanding type 2 diabetes to near-normal may delay the appearance of signs that point to damage to nerves, eyes, and kidneys, but does not stop their progression toward it.

comments 0 comments - Posted Jul 9, 2010

Study Says Byetta and Januvia Do Not Pose Extra Risk for Pancreatitis

A study released in late June has brought some welcome news to the makers of Byetta and Januvia: Users of the two diabetes drugs run no greater risk of developing pancreatitis than people with diabetes who take other drugs. In fact, both drugs seem to put users at slightly less risk for the condition.

comments 0 comments - Posted Jul 8, 2010

AFREZZA Demonstrates Long-Term Efficacy with Type 2s

AFREZZA TM (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, investigational ultra rapid acting mealtime insulin, as part of a diabetes treatment regimen, provides long-term glucose control comparable to usual insulin therapy but with a significantly reduced incidence of hypoglycemia and less weight gain in patients with Type 2 diabetes, according to a two-year study presented at the American Diabetes Association's 70th Scientific Sessions.

comments 0 comments - Posted Jul 6, 2010

GLUMETZA: Extended Release Metformin

Depomed, Inc. and Santarus, Inc. announced new data suggesting that patients previously intolerant of metformin may be able to tolerate higher doses of metformin when treated with GLUMETZA® (metformin HCl extended release tablets).  The finding will be presented at the 70th Scientific Sessions of the American Diabetes Association (ADA) in Orlando. GLUMETZA is a once-daily, extended release formulation of metformin, and is approved for use in adults with type 2 diabetes mellitus. It is promoted in the U.S. by Santarus.

comments 0 comments - Posted Jul 1, 2010

June 2010

Metformin-Avandia Combo Slows Progression to Type 2 in Two-Thirds of At-Risk Patients

A Canadian study that tracked 207 patients suggests that a low-dose combination of metformin and Avandia can reduce the development of type 2 diabetes by 66 percent in people at high risk for the condition.

comments 0 comments - Posted Jun 15, 2010

Low-Dose Aspirin May Not Benefit Younger Diabetes Patients

New guidelines from the American Diabetes Association and two other major medical associations advise not prescribing low-dose aspirin therapy for women under 60 or men under 50 who have diabetes but no other risks for heart disease.

comments 0 comments - Posted Jun 12, 2010

MACUGEN® Improved Vision in Patients with Diabetic Macular Edema

Results from a Phase 3 study demonstrate MACUGEN® (pegaptanib sodium) significantly improved vision in patients with diabetic macular edema (DME), a complication of diabetes that is a leading cause of blindness in people of working age.¹ In the study, 37 percent of patients treated with MACUGEN gained two lines, or 10 letters, of vision on the ETDRS eye chart at 54 weeks, compared to 20 percent of patients who received a sham (placebo-like) procedure which consists of anesthesia and a simulated injection in the eye (p=0.0047). The data were presented at the World Ophthalmology Congress in Berlin by Frank G. Holz, an investigator in the trial and director of the University Eye Hospital at the University of Bonn in Germany.

comments 0 comments - Posted Jun 7, 2010

May 2010

Abnormal Heart Rhythm Risk Increases with Diabetes and Diabetes Medications

A Seattle-based study has found that people with diabetes run a 40 percent increased risk of developing a common type of abnormal heart rhythm known as atrial fibrillation*. The study also shows that as people with diabetes take drugs for the disease, their risk for developing atrial fibrillation increases three percent for each year that they use such medications.

comments 0 comments - Posted May 25, 2010

New Agents That Keep Insulin Working Longer

Scientists at the Mayo Clinic have developed a molecule that can block the breakdown of insulin. Their discovery could lead to development of a new class of drugs to help treat diabetes. 

comments 0 comments - Posted May 10, 2010

Surprise! Metformin Works Differently Than Thought

CINCINNATI - The popular diabetes medication metformin works in different fashion than the current widely accepted view. This new finding could lead to wider use of the drug-particularly in people with cancer.

comments 1 comment - Posted May 4, 2010

April 2010

Smart Insulin

A team of researchers from Case Western University published an article revealing their invention of a "smart" insulin molecule that binds considerably less to cancer receptors and self-assembles under the skin. To provide a slow-release form of insulin, the compound self-assembles under the skin by "stapling" itself together with zinc ions. Zinc staples connect the pieces of the insulin puzzle together to create a functional protein.

comments 0 comments - Posted Apr 23, 2010

Diabetes Drug Tied to Reduced Breast Cancer Risk

The study, published in the journal Diabetes Care, adds to evidence that metformin, a generically available drug commonly used for type 2 diabetes, may have anti-cancer effects.

comments 0 comments - Posted Apr 22, 2010

Synthetic Molecule That Stops Diabetic Inflammation Could Become a Type 2 Therapy

Tests of an experimental drug called CPSI-1306 at Ohio State University were so successful at lowering inflammation and blood sugar levels in lab mice with type 2 diabetes that scientists consider it a prime candidate to become a new therapy for the disease. 

comments 0 comments - Posted Apr 8, 2010

March 2010

The Story of GAD

You may not have heard of GAD, but it's a hot topic in the world of type 1 diabetes research. GAD, which stands for glutamic acid decarboxylase, is an enzyme in the brain and the pancreas that plays several roles in the body. As an enzyme, it converts the excitatory amino acid glutamate into the inhibitory neurotransmitter GABA, which nerve cells use to communicate.  But it also has a less helpful role, as an autoantigen (an element of self that provokes the generation of antibodies) in autoimmune diabetes.

comments 4 comments - Posted Mar 23, 2010

Valsartan (Diovan) Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance

Results from a landmark study involving more than 9,000 people showed that the high blood pressure medicine valsartan (Diovan) delayed progression to type 2 diabetes in patients with cardiovascular disease or risk factors and impaired glucose tolerance (IGT), a common pre-diabetic condition.

comments 0 comments - Posted Mar 20, 2010

Mutation That Affects Response to Smell and Taste Could Lead to Type 2 Diabetes

According to Duke University researchers, a mutation that causes the lack of an insulin-controlling molecule may be a factor in the development of type 2 diabetes. The molecule, ankyrin B, is activated in response to the smell and taste of food and leads to the production of insulin in preparation for food intake.

comments 1 comment - Posted Mar 19, 2010

Dolphins' Ability to Switch Diabetes On and Off Could Point to a Similar Knack in Humans

A scientist's discovery that dolphins have a genetic ability to turn diabetes on and off, depending on the availability of food, could lead to research into whether humans might have a similar-although dormant-gene.

comments 1 comment - Posted Mar 13, 2010

Northern California's Biggest County Sues Glaxo Over Avandia

Santa Clara County, the largest county in Northern California (nearly 1.9 million people), has filed a federal lawsuit against pharmaceutical company GlaxoSmithKline, alleging that Glaxo knowingly sold its type 2 diabetes drug Avandia for several years despite indications the drug causes heart attacks and strokes.

comments 0 comments - Posted Mar 9, 2010

February 2010

GSK rejects conclusions of Senate Committee on Finance Staff Report on Avandia

The Staff Report of the Senate Committee on Finance draws conclusions on the safety of Avandia (rosiglitazone) that are based on analyses that are not consistent with the rigorous scientific evidence supporting the safety of the drug. In addition, the report cherry-picks information from documents, which mischaracterizes GlaxoSmithKline's comprehensive efforts to research Avandia and communicate those findings to regulators, physicians and patients. In fact, the safety and effectiveness of Avandia is well characterized in the label approved by the FDA.

comments 1 comment - Posted Feb 23, 2010

U.S. Senate Report Says Glaxo Knew that Avandia Increases Risk of Heart Attacks

A U.S. Senate Finance Committee report released on February 20 says that Avandia, GlaxoSmithKline's drug for type 2 diabetes, may have caused as many as 83,000 heart attacks between 1999, when the drug was introduced, and 2007. The Senate report, culminating a two-year inquiry into the drug, also says that Glaxo knew about the drug's potential risks years before suspicions began to form regarding a connection between Avandia and heart problems.

comments 2 comments - Posted Feb 22, 2010

December 2009

Evidence Deepens That Breastfeeding Helps Moms Avoid Metabolic Syndrome and Type 2

A 20-year study that tracked 704 women from before their first pregnancy onward suggests that the first year mothers breastfeed, they reduce their risk of acquiring type 2 diabetes within the next 15 years by 15 percent. Each subsequent year of breastfeeding further reduces the risk by 15 percent. For example, a mother who has two children and breastfeeds each for a year could enjoy a 30 percent reduction in her risk of type 2 over a 15-year period.

comments 2 comments - Posted Dec 25, 2009

Good Fat, Bad Fat

FRIDAY, Dec. 18 (HealthDay News) -- Blacks tend to carry around less of a particularly unhealthy type of abdominal fat than whites, even though they suffer more from obesity-linked illness, researchers report.

comments 0 comments - Posted Dec 23, 2009

Review of Clinical Trials of Oral Insulin: Oral-lyn

WORCESTER, Mass., Dec 3, 2009 (GlobeNewswire via COMTEX News Network) -- Published in the journal Diabetes, Obesity and Metabolism, an independent review of clinical trials of Generex Oral-lyn(TM) shows that the oral insulin spray has a faster onset of action and shorter duration of action than insulin delivered subcutaneously.

comments 6 comments - Posted Dec 9, 2009

IBsolvMIR®, a Drug That Prevents Islet Transplantation Rejection, Receives FDA -Orphan Drug- Status

A Swedish biotechnology company, TikoMed AB, has received notice that the U.S. Food and Drug Administration is granting orphan drug designation to its IBsolvMIR® drug for preventing the rejection of transplanted pancreatic islet cells in type 1 patients.

comments 0 comments - Posted Dec 4, 2009

October 2009

Grapefruit and Metformin May Have Ill Effects on the Body's pH Levels

A South African university pharmacologist has found that simultaneous consumption of metformin and grapefruit juice raises lactic acid to dangerous levels in rats (and conceivably in people) with type 2 diabetes. Too much acid in the blood can cause low pH levels that interfere with the body's metabolic functions. Conceivably, says Dr. Peter Owira, a pharmacologist at the University of KawZulu-Natal, such low levels could be fatal.

comments 6 comments - Posted Oct 26, 2009

Afresa: Waiting to Inhale

So close, and yet so far.  It looks like there will be no marketing partnership for MannKind's ultra rapid-acting insulin product Afresa anytime soon.  The company had planned to enter into a deal with a large pharmaceutical company by the end of this year, but now approval from the Food and Drug Administration (FDA) for their inhaled insulin won't be until January 2010, at the earliest.

comments 3 comments - Posted Oct 8, 2009

Phentermine the Phoenix Rises Again

The demise of Fen-phen dealt a body blow to hopes for an obesity pill that is actually effective. Unfortunately, the fen in Fen-phen, fenfluramine, caused grave pulmonary hypertension and heart valve problems. The phen part of the drug, though, was apparently just an innocent bystander. And now phen (phentermine) has resurfaced in a new pill that has posted some amazing results in Phase III clinical trials. Patients who were treated for 56 weeks with the new drug, Qnexa, lost an average of 14.7 percent of their weight, or 37 pounds.

comments 8 comments - Posted Oct 7, 2009

The Connection Between Allergies and Kidney Disease in Men with Type 2

A study coming out in the November issue of the Clinical Journal of the American Society of Nephrology is reporting that type 2 men whose blood contained a high count of eosinophils, a sign of allergic inflammation, also had albumin in their urine, which is an early indication of kidney disease. Eosinophils are white blood cells that increase in number during an allergic reaction. Albumin is a protein in the blood that helps regulate blood volume and acts as a carrier for other molecules. Albumin is not normally found in the urine, however, because when healthy kidneys filter the blood, they retain what the body needs (like proteins) and allow only smaller "impurities" into the urine. But during diabetes, too much blood sugar can damage the filtering structures of the kidneys, causing them to thicken and become scarred. Eventually, they begin to leak, and protein (albumin) begins to pass into the urine.

comments 0 comments - Posted Oct 6, 2009

Afresa: A New Insulin (By the Way, It's Inhaled)

The enthusiasm for inhaled insulin has waned, to say the least, since Exubera was pulled off the market by Pfizer. Following the Exubera debacle, the development of two other inhaled insulins (AIR by Eli Lilly and Alkermes, and AERx by Novo Nordisk) was halted as well.

comments 14 comments - Posted Oct 5, 2009

September 2009

Januvia and Janumet Join the Pancreatitis Controversy

Clinical trials are conducted before a new drug is released for sale, in part to test for bad things that might happen when people take it. But clinical trials don't involve all that many people: several thousand at the most. After the clinical trials are successfully completed, however, the drug is sold to millions upon millions.  Merck's sales of Januvia and Janumet, for example, totaled over a billion dollars in the first six months of this year alone.

comments 1 comment - Posted Sep 30, 2009

Mighty Metformin: The New Cancer Wonder Drug

Metformin has always been the old reliable for treating new onset type 2 diabetes, but it's beginning to look like it's got a new calling as a cancer treatment. Diabetes Health recently reported on the fact that metformin reduces a type 2 person's risk of pancreatic cancer by up to 62 percent. It's also been observed that people with type 2 who take metformin have a much lower cancer incidence than those who don't. Now it appears that metformin can help with breast cancer treatment as well. A study of mice with breast cancer generated from human breast cancer cells has found that they remained tumor-free for nearly three months on metformin combined with doxorubicin, a standard cancer chemotherapy. In mice given only the doxorubicin, the tumors recurred.

comments 1 comment - Posted Sep 25, 2009

August 2009

Japanese Company's Stock Jumps 10 Percent on News of Insulin Nasal Spray

A Japanese company whose biggest moneymaker is the sale of synthetic fabrics announced a few days ago that it has developed an insulin nasal spray for people with diabetes. The news brought an investor surge that lifted the value of its stocks by 10 percent.

comments 0 comments - Posted Aug 28, 2009

Once-a-Month Dosing for Type 2s?

A new glucagon-like peptide-1 (GLP-1) analog for type 2s that might require dosing only once a month is now in pre-clinical (animal) studies.  GLP-1, which increases insulin secretion from the pancreas, is a mighty helpful molecule, but with a sadly brief lifespan. It's broken down in the body within minutes by the enzyme DPP-4.  That's why drugs like Merck's Januvia, a DPP-4 inhibitor, is effective: blocking DPP-4 subsequently increases the amount of GLP-1 in the system.  

comments 0 comments - Posted Aug 25, 2009

July 2009

Considerable Risk of Cardiovascular Events May Linger Despite Achieving Target LDL Cholesterol Levels with Statins in Patients with Metabolic Syndrome

May 5 - Ann Arbor, MI - In the first study of the effects of statins on the concentrations of both low-density lipoprotein cholesterol (LDL-C; known as the "bad" cholesterol) and low-density lipoprotein particles (LDL-P) in patients with metabolic syndrome, it was shown that even though the statins lowered the concentrations of LDL-C to target levels, the patients retained considerable residual risk for cardiovascular events because LDL-P concentrations were not reduced to a similar extent.  A pre-print version of the study in Diabetes Care is available online at, and the final version will be available in print in the June 2009 issue, as well as online at the same URL.

comments 0 comments - Posted Jul 29, 2009

Interferon Alpha Can Delay Full Onset of Type 1 Diabetes

According to results of a phase II clinical trial at the University of Texas Medical School, a low dose of oral interferon alpha can preserve pancreatic beta cell function in newly diagnosed type 1 diabetes patients. Interferons are proteins produced by the cells of the immune system in response to challenges like a virus or a tumor cell. They work by inhibiting viral replication in the host cell, activating natural killer cells, and increasing the activity of other immune system cells such as lymphocytes.

comments 0 comments - Posted Jul 24, 2009

Cardiologists Say Give Statins to People Even If They Don't Have Heart Disease

An analysis of ten trials involving statin therapy among 70,000 participants has led an international team of cardiologists to recommend that that the cholesterol-lowering drugs be prescribed for people who do not have heart disease.

comments 2 comments - Posted Jul 15, 2009

ID Genetic Markers That Could Improve Effectiveness of Diabetes Therapies

Scientists have identified five genetic biomarkers that predict how well a type 2 patient will respond to the drug Actos. Their work could be the first step toward a system that would allow doctors to predetermine which drugs will best help each person with diabetes. 

comments 0 comments - Posted Jul 3, 2009

Genentech Buys $350 Million Stake in Drug Designed to Stop Autoimmune Attacks in Type 1s

Genentech, a bioscience firm famous for its development of antibodies designed to combat cancer, has entered a $350 million agreement with Bayhill Therapeutics to assist in development of BHT-3021, a drug that treats type 1 diabetes by reducing or stopping immune system attacks on pancreatic beta cells.

comments 2 comments - Posted Jul 1, 2009

June 2009

Doctors Urged to Stop Accepting Bri- —Oops, Make That Gifts—From Big Pharma

Drug companies spend billions of dollars on research, and it's obvious that they spend more billions on advertising. Well, according to the New York Times, they spend the most billions on giving nice things to doctors: pens, samples, banquets, trips, and educational opportunities among them. For doctors, in fact, there is a free lunch: Pharma companies spend as much as a billion a year just on lunches for doctors. And over 90 percent of doctors have accepted at least some of this largesse from the industry.

comments 5 comments - Posted Jun 12, 2009

Foot Amputation Risk in Type 2s Reduced 36 Percent By Blood Fat-Lowering Drug

Patients with type 2 diabetes reduced their risk of having a foot amputated by 36 percent when they took fenofibrate, a drug designed to lower blood fat levels.

comments 0 comments - Posted Jun 12, 2009

The Lowly Sewer Bacterium That Likes to Bust Up Cholesterol

Spanish university researchers have isolated a new species of bacteria-which they found in sewer sludge-that is able to break down cholesterol.

comments 0 comments - Posted Jun 4, 2009

Metformin Add-on Drops Fasting Glucose Levels by 12 Points in Phase 2 Trial

CRx-401, an insulin sensitizer intended to assist metformin in type 2 diabetes therapy, has successfully completed a Phase 2 clinical trial in which patients taking it saw their fasting plasma glucose drop by 12 mg/dl after 90 days.

comments 1 comment - Posted Jun 3, 2009

May 2009

New Type 2 Drug, Welchol, Discussed at the AACE Conference Reduces A1c's and LDL Cholesterol

In a recent 16-week randomized, open-label pilot study, 169 patients were randomized to receive Welchol (n=57), Januvia (n=56), or Avandia (n=56).1  The results demonstrated that Welchol (colesevelam HCl) significantly improved glycemic control and reduced mean LDL cholesterol (LDL-C) when added to metformin monotherapy in patients with type 2 diabetes. In the study, Januvia® (sitagliptin) and Avandia® (rosiglitazone) also significantly improved glycemic control, but LDL-C increased in patients on both of these treatment regimens.

comments 0 comments - Posted May 29, 2009

Peptide Used to Combat Alzheimer’s Found to Be Powerful Insulin Regulator

Humanin (HN) is a mitochondrial peptide* that in some research has shown the ability to protect against the death of neurons, the devastating consequence of diseases like Alzheimer's. According to the leader of a research team at the Albert Einstein College of Medicine at Yeshiva University in the Bronx, however, it also significantly improves the insulin sensitivity of diabetic rats and sharply drops their glucose levels.

comments 2 comments - Posted May 20, 2009

Resolvins, Discovered in Omega-3 Fatty Acids, Show Ability to Restore Lost Gum Disease Tissue and Bone

Dental researchers are reporting that resolvins, products derived from omega-3 fatty acids, may have the ability to restore the soft tissue and even bone lost in periodontal (gum) disease.

comments 0 comments - Posted May 7, 2009

Type 2 Drugs: EU Approves “Victoza,” FDA Extends Review of “Onglyza”

The European Union's drug regulation agency has recommended that the EU approve the marketing of "Victoza" (liraglutide), a type 2 drug developed by Novo Nordisk.

comments 2 comments - Posted May 6, 2009

Common Glucose-Control Drug May Delay or Even Prevent Onset of Type 2

Voglibose*, a generic drug often used in combination with sulfonylureas to control blood glucose levels, appears to delay or even prevent the onset of diabetes in people who are predisposed to the disease.

comments 6 comments - Posted May 1, 2009

April 2009

Long-Acting Byetta Tops Two Other Diabetes Drugs in Direct Comparison

Results from DURATION-2, a 26-week test comparing the diabetic drugs Januvia, Actos, and experimental long-acting Byetta (Byetta LAR) show that Byetta produced lower A1c's and more weight loss than the other two drugs.

comments 5 comments - Posted Apr 15, 2009

Altea Partners With Amylin and Lilly to Develop 12-Hour Byetta Skin Patch

Buoyed by its recent successful phase 1 human clinical trial of a patch that delivers basal insulin through the skin, Atlanta-based Altea Therapeutics says it will work with Eli Lilly and Company and Amylin Pharmaceuticals, Inc., to develop a daily transdermal patch that deliver sustained levels of Byetta (exenatide). The patch, in a 12- and a 24-hour form, will use the company's proprietary PassPort Transdermal Delivery System. Lilly and Amylin will fund all development, manufacturing, and marketing activities for the product. 

comments 2 comments - Posted Apr 7, 2009

Tobacco as Medicine?

Last week we published an article about how the CDC says too many people are still smoking. The federal government has a Healthy People 2010 goal of reducing adult smoking rates to 12 percent or less by 2010. Of the 50 states, only Utah has thus far achieved that goal. 

comments 1 comment - Posted Apr 2, 2009

March 2009

Drug Based on Enzyme Found in Insects Enters Phase IIa Trial for Treatment of Type 2, Other Inflammatory Diseases

AR9281, a drug developed by the University of California at Davis and now under further development by a California-based pharmaceutical company, has entered Phase II of human clinical trials.

comments 1 comment - Posted Mar 27, 2009

Experts Affirm That Low-Dose Aspirin Daily Can Help Prevent Heart Attack and Stroke

New guidelines from the U.S. Preventive Services Task Force state that daily low doses of aspirin-75 milligrams to 81 milligrams-are as effective as higher doses (100+ milligrams) in preventing heart attacks among men and strokes among women. 

comments 3 comments - Posted Mar 26, 2009

Insulin For Type 2 Diabetes: Who, When, And Why?

Physicians who treat people with type 2 diabetes face difficult choices when selecting the best medical therapy for each patient. The decision process is further complicated by the fact that because type 2 diabetes is a progressive disease, therapeutic agents that were initially successful may fail five or ten years later.

comments 159 comments - Posted Mar 20, 2009

JDRF-Funded Study Takes First Step Toward Development of Medicines That Can Regenerate Pancreases

Researchers funded by the Juvenile Diabetes Research Foundation have found two chemical compounds that can trigger the growth of insulin-producing beta cells in the pancreas. The discovery could become the basis for medicines designed to regenerate the pancreas in people with type 1 diabetes.

comments 9 comments - Posted Mar 11, 2009

Recently Discovered Diabetes “Biomarker” Could Lead to Earlier Detection

A complex sugar derived from glucose during the body’s metabolic processes could be a way to reliably detect a pre-diabetes condition, say researchers at the Johns Hopkins University School of Medicine in Baltimore. If it does, the “biomarker” (an indicator of an organism’s state of health) could provide enough early warning that patients nearing the onset of type 2 diabetes could take steps to slow or even halt it through lifestyle changes.

comments 1 comment - Posted Mar 3, 2009

February 2009

Type 2 Drug Improves Glucose Metabolization by 41% in Clinical Trial

DM-99, a drug under development by the Canadian drug company DiaMedica, Inc., has just finished a phase 2a "proof of concept" trial with 40 type 2 patients in Europe. Although the company did not release performance figures from the trial, it found them sufficiently encouraging to move further into phase 2 testing.

comments 0 comments - Posted Feb 26, 2009

Sulfonylureas, If Used Quickly, Appear to Reverse Neonatal Diabetes

A report in the February 4, 2009, issue of Cell Metabolism says that babies born with neonatal diabetes might be able to avoid irreversible damage to the pancreas if doctors treat them quickly with sulfonylureas rather than insulin.

comments 0 comments - Posted Feb 25, 2009

Vaccine to Suppress Type 1 Onset in At-Risk Children Could Be Based on Enzyme

Georgia researchers believe that a powerful enzyme that inhibits or modifies immune system response could be the basis for a vaccine administered to children at high risk for developing type 1 diabetes.

comments 0 comments - Posted Feb 25, 2009

Erectile Dysfunction Pill for Men with Diabetes Enters Phase 3

Avanafil, a pill that may permit diabetic men who are experiencing erectile dysfunction to engage in intercourse without the restrictions on food or alcoholic intake associated with other ED treatments, is entering a second phase 3 study-the crucial step before a drug manufacturer seeks FDA or European approval to market.

comments 5 comments - Posted Feb 24, 2009

Liraglutide Best at Reducing A1c’s When Used in a Two-Drug Combo

Data from a phase 3 study of the Novo Nordisk drug liraglutide shows that when it is used in combination with glimepiride, it is more effective at reducing A1c's than glimepiride by itself or glimepiride in combination with the drug rosiglitazone. 

comments 0 comments - Posted Feb 19, 2009

Adult Beta Cells Coaxed into Replicating

By introducing a protein called cdk6 into human insulin-producing adult beta cells via a virus, University of Pittsburgh School of Medicine researchers have induced the cells to replicate "robustly." Previously, scientists believed that beta cells could be induced to regenerate slowly at best, and usually not at all. 

comments 0 comments - Posted Feb 5, 2009

January 2009

The Trojan Horse: Sneaking Insulin into the Digestive System by Hiding It in a Vitamin

Syracuse University chemist Robert Doyle has taken out a patent on something that has long been a Holy Grail for insulin suppliers and users: a reliable way to take insulin orally instead of with a needle.

comments 4 comments - Posted Jan 28, 2009

An Update on Salsalate, an Aspirin-Like Drug That Lowers Blood Glucose and Fights Inflammation

We first reported on salsalate, an aspirin-like drug discovered in the nineteenth century, last October. At that time, researchers at the Joslin Diabetes Center in Boston discovered that it appears to reduce inflammation and lower blood glucose in people with type 2 diabetes.

comments 2 comments - Posted Jan 27, 2009

Antioxidants Relieve Pain of Chronic Pancreatitis

For patients who suffer frequent sharp abdominal pain from chronic pancreatitis, antioxidants may offer effective pain relief, according to a study recently published in Gastroenterology, the journal of the American Gastroenterological Association Institute.

comments 5 comments - Posted Jan 23, 2009

Pre-Existing Drugs May Restore Sensitivity to Leptin, an Appetite Suppressing Hormone

Hearts in the medical community beat with considerable excitement at the discovery of leptin in 1994. A hormone produced by fat, leptin has a very useful talent: it tells the brain when to stop eating. So hopes were high that leptin would become the basis of an anti-obesity treatment. What could be simpler than to dose an obese person with a hormone that says, "You're not hungry any more, and you want to stop eating."

comments 0 comments - Posted Jan 22, 2009

Protein That Helps Form Organs Could Control Obesity and Diabetes

According to biologists at the Baylor College of Medicine, limiting the copies of a gene that produces a protein affecting organ development serves to decrease fat cell size in mice, enhance their responsiveness to insulin, and increase their energy level.

comments 0 comments - Posted Jan 14, 2009

December 2008

Small Bedtime Dose of Terbutaline May Prevent Type 1 Hypoglycemia
Small Bedtime Dose of Terbutaline May Prevent Type 1 Hypoglycemia

A study of the effectiveness of the drug terbutaline on controlling nighttime hypoglycemia in people with type 1 diabetes indicates that it may be a safe and useful treatment with no ill effects.

comments 5 comments - Posted Dec 29, 2008

Women Have Double the Fracture Risk with Avandia and Actos

Avandia (rosiglitazone) and Actos (pioglitazone), two medications used to lower blood sugar in type 2 patients, double the risk of fractures in women, but not in men, says a new study.

comments 0 comments - Posted Dec 22, 2008

November 2008

Anti-Cancer Drugs in Lab Mice Trials Prevent or Reverse Type 1
Anti-Cancer Drugs in Lab Mice Trials Prevent or Reverse Type 1

Researchers at the University of California, San Francisco, have found that two drugs used to treat cancer can prevent or cure type 1 diabetes in mice.

comments 7 comments - Posted Nov 24, 2008

An Old Diabetes Drug Standby Might Lower Heart Risks

Metformin, the tried-and-true diabetes drug that is prescribed to many type 2s when they are first diagnosed, may decrease the risk of death from cardiovascular disease. That's the conclusion of a meta-analysis by researchers at the Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland. 

comments 0 comments - Posted Nov 3, 2008

The Cost of Progress

The annual cost for drugs to treat type 2 diabetes nearly doubled between 2001 and 20, skyrocketing from $6.7 billion in 2001 to $12.5 billion six years later, according to researchers from Stanford University and the University of Chicago.

comments 0 comments - Posted Nov 3, 2008

October 2008

New Data From Phase 3 Trial Says Liraglutide Is More Effective Than Exenatide For Type 2s

Novo Nordisk recently announced results from its LEAD 6 study showing that once daily liraglutide was significantly more effective at improving blood glucose control (as measured by A1c) than exenatide, a GLP-1 mimetic administered twice daily.

comments 4 comments - Posted Oct 27, 2008

New Drug Shows Exenatide-Like Promise in Type 2 Treatment

An experimental exenatide (Byetta)-like drug called liraglutide has shown the ability to enhance insulin and glucagon production and suppress appetite in type 2 patients, according to a report in the British medical journal The Lancet.

comments 0 comments - Posted Oct 13, 2008

Salsalate, an Aspirin-Like Drug, Shows Promise as a Type 2 Prevention

An aspirin-like drug discovered 132 years ago may prove to be a powerful weapon against type 2 diabetes.

comments 3 comments - Posted Oct 13, 2008

September 2008

Good News for Byetta (Exenatide): Canadian Study Reports Once-Weekly Dose Is Better at BG Control Than Twice Daily

A Canadian clinical study has delivered a double dose of good news for proponents of exenatide (sold commercially as Byetta), a drug used by more than 700,000 Americans to control blood glucose, ease food cravings, and, incidentally, lose weight.  

comments 3 comments - Posted Sep 11, 2008

July 2008

Type 2 Diabetes: Is Carb Counting Unnecessary?
Type 2 Diabetes: Is Carb Counting Unnecessary?

You’ve got type 2 diabetes. A few years ago, you started using a long-acting insulin once a day, and your fasting glucose levels and your A1c came down. But now your A1c is creeping back up. Your doctor tells you that you need to add a mealtime insulin to your plan.

comments 2 comments - Posted Jul 31, 2008

The FDA Ponders Tougher Hurdles For New Diabetes Drugs
The FDA Ponders Tougher Hurdles For New Diabetes Drugs

The Food and Drug Administration is considering a requirement that before receiving agency approval, new diabetes treatment drugs must not only lower blood sugar levels, but also demonstrate a positive effect on heart disease and lifespan.

comments 1 comment - Posted Jul 3, 2008

October 2007

Actos and Avandia Cost Plenty

According to Greek researchers, Actos and Avandia were behind a tripling of the cost of medicines used to treat Athenians with type 2 diabetes over the past eight years.

comments 0 comments - Posted Oct 10, 2007

August 2007

An Antique Malaria Drug May Reduce Risk of Type 2 Diabetes

An old and inexpensive drug, hydroxychloroquine, has been found to help prevent type 2 diabetes in people with rheumatoid arthritis.

comments 0 comments - Posted Aug 19, 2007

April 2007

Breathalyzer Test for Diabetes In the Offing?

It’s well known that people with uncontrolled diabetes sometimes suffer from ketoacidosis, in which their breath gives off the strong odor of nail polish remover. Well, nail polish remover is made of acetone.

comments 0 comments - Posted Apr 10, 2007

February 2007

Statins Help Hearts of People with Diabetes

According to Reuters Health, a study appearing in the October 2006 issue of European Heart Journal found that people with diabetes who have suffered a heart attack or episode of severe angina benefit just as much from treatment with statins as those without diabetes.

comments 0 comments - Posted Feb 1, 2007

September 2006

Oral Meds Research

Starlix Found to Reduce Liver Fat

comments 0 comments - Posted Sep 1, 2006

January 2006

Is Pargluva On the Ropes?

It was the belle of the ball at last summer’s ADA Scientific Sessions in San Diego. Now it appears that muraglitazar (Pargluva) is clinging to life after a scathing report recently published by the Journal of the American Medical Association.

comments 0 comments - Posted Jan 1, 2006

April 2004

Aspirin Benefit Blunted in People With Diabetes

An aspirin a day has long been a low-cost preventive therapy to reduce cardiovascular events.

comments 0 comments - Posted Apr 1, 2004

March 2004

Cut Through the Fat

Researchers have long understood that thiazolidinediones (TZDs) improve the action of insulin while increasing total fat mass as well. After studying 39 upper-body obese, insulin-resistant, but non-diabetic men and postmenopausal women, researchers concluded that patients on pioglitazone (Actos) improved their insulin resistance level regardless of the rise in intra-abdominal fat that accompanied the therapy.

comments 0 comments - Posted Mar 1, 2004

February 2004

Pravachol: How Cholesterol-Lowering May Help You

The cholesterol-lowering drug Pravachol (pravastatin), when administered at 40 milligrams per day over six years, helps prevent cardiovascular events including stroke in people with diabetes or with impaired fasting glucose (IFG) and established coronary disease.

comments 0 comments - Posted Feb 1, 2004

New Pill May Work Cardiovascular Wonders

It seems too good to be true, but researchers from Queen Mary’s School of Medicine and Dentistry in London are advancing a new therapy to reduce the cardiovascular risk factors of high blood cholesterol, blood pressure, blood homocysteine levels, and platelet clumping—all in one pill.

comments 0 comments - Posted Feb 1, 2004

Inhaled Insulin in Development

Bristol-Myers Squibb and QDose have announced a collaboration to develop inhaled insulin.

comments 0 comments - Posted Feb 1, 2004

March 2003

Diuretics Better for Blood Pressure than More Expensive Drugs

What's the best drug to combat high blood pressure and lower the incidence of heart failure and hospitalization for heart failure?

comments 0 comments - Posted Mar 1, 2003

December 2002

Diabetes Medication Associated With Weight Gain

Your doctor diagnoses you with type 2 diabetes and advises you to lose weight—and then gives you a prescription for a medication that is known to cause excessive weight gain.

comments 0 comments - Posted Dec 1, 2002

Prandin Versus Glucophage

When combined with NPH insulin taken at bedtime, Glucophage (metformin) provides slightly better glucose control with less weight gain and improved satisfaction with diabetes treatment than Prandin (repaglinide) plus NPH, say researchers in the United Kingdom.

comments 0 comments - Posted Dec 1, 2002

Eli Lilly, Amylin to Collaborate on Potential Diabetes Treatment

Eli Lilly and Company of Indianapolis, Indiana, and Amylin Pharmaceuticals of San Diego, California, have formed a global agreement to collaborate on development and sale of a potential new treatment for type 2 diabetes.

comments 0 comments - Posted Dec 1, 2002

November 2002

Weighing the Evidence: Blood Glucose Levels Decrease with Insulin Sensitizer Despite Weight Increase

A shift in fat distribution from visceral (the internal abdominal area) to subcutaneous (under the skin) could be the reason the insulin sensitizer Actos (pioglitazone) helps to lower blood glucose levels in people with insulin resistance.

comments 0 comments - Posted Nov 1, 2002

Oh, the Irony—Does an Insulin Maker’s Schizophrenia Drug Cause Diabetes?

Zyprexa (olanzapine), which belongs to a family of drugs known as atypical anti-psychotics, could be a factor in the development of diabetes.

comments 0 comments - Posted Nov 1, 2002

October 2002

Novo Nordisk Suspends Development of Insulin Sensitizer - Tumors Found in Animal Tests

Novo Nordisk has suspended development of ragaglitazar - a drug that has potential for regulating both blood-glucose and lipid levels-after finding urine bladder tumors in one mouse and several rats tested with the drug during preclinical trials.

comments 0 comments - Posted Oct 1, 2002

September 2002

Oral Insulin Products Under Development

An agreement to develop and market orally administered insulin products, which might total as much as $238 million, has been signed by GlaxoSmithKline of London and Nobex Corporation of Research Triangle Park, North Carolina.

comments 0 comments - Posted Sep 1, 2002

Birth Control Pills May Also Help Prevent Diabetes

Combination oral contraceptives may do more than prevent unwanted pregnancies—they also may help prevent diabetes.

comments 0 comments - Posted Sep 1, 2002

August 2002

Oral Medication Options for Treating Type 2 Diabetes

Over the past seven years, the number of oral drug therapies for the treatment of type 2 diabetes has dramatically increased. Of the six basic types of medication that can help normalize your blood glucose, five are available as oral drugs.

comments 0 comments - Posted Aug 1, 2002

April 2002

Altered Insulin

Imagine being able to "turn on" your insulin, telling it when to start working, instead of having to take your injections at certain times during the day. Researchers from the University of California at San Diego believe they may have discovered a way to do this—at least in rats.

comments 0 comments - Posted Apr 1, 2002

November 2001

One Down

Researchers in the United Kingdom say that the anti-rejection medication sirolimus (Rapamune) allows for the early withdrawal of the anti-rejection drug cyclosporine in people who have had a kidney transplant.

comments 0 comments - Posted Nov 1, 2001

Two New Oral Insulins on the Horizon

Emisphere Technologies Inc., of Tarrytown, New Jersey announced the results of three phase I studies for two new medications for the oral delivery of insulin. Representatives, who presented the data at Investor Day In New York City and released a written statement on September 7, said the trials showed that the drugs were successfully absorbed from the gastrointestinal tract and significantly reduced blood glucose levels in study subjects.

comments 0 comments - Posted Nov 1, 2001

September 2001

One Better Than the Other

Australian researchers are saying the angiotensin-converting enzyme (ACE) inhibitor perindopril (Aceon) is more effective than the calcium channel blocker nifedipine (Procardia) in slowing the progression of kidney disease in people with diabetes who have normal blood pressure.

comments 0 comments - Posted Sep 1, 2001

May 2001

A Side Effect Worth Noting

Heart disease medicine may protect people from diabetes, say researchers in the January 23 issue of Circulation: The Journal of the American Heart Association.

comments 0 comments - Posted May 1, 2001

Aspirin Shown to Help Prevent Heart Failure in People with Diabetes

Aspirin has been shown to help prevent heart disease among people with diabetes. The American Diabetes Association (ADA) has recommended the over-the-counter pain reliever to diabetic adults who have cardiovascular disease or are at risk for it.

comments 0 comments - Posted May 1, 2001

January 2001

Avandia to be to Studied for Prevention of Type 2 Diabetes

SmithKline Beecham announced in a November 8, 2000 press release that its type 2 drug Avandia (rosiglitazone) will be the only diabetes drug studied in a first-of-its kind, multi-national, 4,000-person study to determine the impact of intensive drug therapy on preventing type 2 diabetes.

comments 0 comments - Posted Jan 1, 2001

September 2000

Viagra: Not Just For Erectile Dysfunction Anymore

Viagra, the anti-impotence drug manufactured by Pfizer, may also be an effective remedy against gastroparesis, a common digestive condition among people with diabetes.

comments 0 comments - Posted Sep 1, 2000

April 2000

Warehousing Insulin

Through gene therapy, scientists at Ariad Pharmaceuticals in Cambridge, Massachusetts, have come up with a way to store insulin in cells that can be released only when a pill is taken. Published in the February issue of Science, the findings hold promise not just for the treatment of diabetes, but for other medical problems which require a timed-release technique.

comments 0 comments - Posted Apr 1, 2000

January 2000

Study Will Compare Avandia’s Effect on Treatment of Type 2 Complications

SmithKline Beecham recently announced plans to initiate a major study to determine if early treatment with Avandia, Glucophage or a sulfonylurea improves and maintains blood sugar control in patients with type 2 diabetes, delays and/or prevents complications such as kidney disease and prevents decline in pancreatic beta-cell function.

comments 0 comments - Posted Jan 1, 2000

September 1999

Avandia and ACTOS Hit The Ground Running—Rezulin Competitors Show No Liver Toxicity in Clinical Trials

Two new drugs have received approval from the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes. In clinical trials, Avandia (rosiglitazone maleate) and ACTOS (pioglitazone hydrochloride) lowered blood sugars an average of 76 mg/dl and 95 mg/dl respectively, when compared to a placebo.

comments 0 comments - Posted Sep 1, 1999

July 1999

Pill May Some Day Lower Blood Sugars

A compound isolated from a fungus controlled blood glucose levels in mice bred to develop diabetes. Researchers are saying that if the fungus, collected from a plant in the Republic of Congo, demonstrates the same effects in humans with diabetes, then millions of people would be freed from taking insulin.

comments 0 comments - Posted Jul 1, 1999

May 1999

Calcium Channel Blockers Reduce Stroke and Heart Trouble in Elderly People with Diabetes

Treatment with nitrendipine, a calcium channel blocker, was proven to be beneficial in older patients with diabetes and hypertension.

comments 0 comments - Posted May 1, 1999

September 1998

Do Sulphonylurea Drugs Cause Heart Attack?

In the June issue of Diabetologia: the Journal of the European Association for the Study of Diabetes, researchers argued whether sulphonylurea drugs (such as Micronase, Glucotrol, DiaBeta, Glynase, Amaryl and Diabinese) pose an increased cardiovascular risk for individuals with type 2 diabetes and heart disease. (Sulphonylurea drugs are prescribed to help stimulate the beta cells of individuals with type 2 diabetes; it may also increase the sensitivity of muscle tissue to the hormone.)

comments 0 comments - Posted Sep 1, 1998

February 1997

Dexamethasone Halts Rare Complication of Type 1 Diabetes

A new treatment method has been discovered for lipoatrophy, a rare but problematic complication of type 1 diabetes. The condition is an adverse effect of the immune system's interaction with insulin that results in dents in the skin at insulin injection sites. These dents are caused by atrophy of the tissue directly beneath the skin.

comments 0 comments - Posted Feb 1, 1997

January 1997

Protein Targeted to Prevent Kidney Disease

The Philadelphia-based Exocell, Inc. has recently signed an agreement with Eurand International for the clinical development of an orally administered compound that could help prevent diabetic kidney disease. The compound, EXO-226, will be produced and supplied by Eurand for use in the first phase of clinical trials for FDA approval. Exocell anticipates that these trials will begin in early 1997.

comments 0 comments - Posted Jan 1, 1997

February 1996

Letters from Readers

Troglitazone is a new insulin-action enhancer currently in the third phase of clinical testing. Parke-Davis Pharmaceutical Research has announced that a pilot study at St. Joseph Hospital in Ann Arbor, Mich., showed that the drug lowers blood glucose levels in patients with type 2 diabetes. The study also found that the drug can help reduce and even eliminate daily insulin injections in type 2 diabetics.

comments 0 comments - Posted Feb 1, 1996

September 1995

Prevent Complications: Will it be Possible?

The causes of diabetic complications are not yet completely understood, but there are some strong suspicions about certain changes in tissues and organs. It seems almost undeniable (especially after the recent DCCT) that hyperglycemia plays a major role in triggering the mechanisms that ultimately lead to diabetic complications. Two of the suspected mechanisms are osmotic effects from the hyperglycemia itself and glycosylation (glucose sticking to other molecules) of various important proteins-like hemoglobin, and the tissues of the eye, kidney, nerve, and blood vessels. Also suspected is the accelerated action of some enzyme systems when they are fed by extra glucose.

comments 0 comments - Posted Sep 1, 1995

March 1995

Drug Watch: Two Treatments Which May Need More Scrutiny:

Though it may be a promising alternative for many people with type 2 diabetes, the drug metformin may cause severe side effects, even death, in some patients.

comments 0 comments - Posted Mar 1, 1995

September 1991

Imuran Or Insulin?

We have known for years that insulin-dependent diabetes begins when a patient's immune system attacks and destroys its own insulin-producing cells. A logical strategy is to thwart the immune attack through drug intervention. In 1984, several newly diagnosed diabetics were treated with the immune-suppressing drug Imuran. Unfortunately, those tested had already lost a large proportion of their insulin-producing cells. As a result, most of those tested were able to come off insulin for only a brief period of time. The key, specialists say, is to administer the Imuran before any overt symptoms of diabetes appear.

comments 0 comments - Posted Sep 1, 1991

©1991-2015 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.